EA015566B1 - Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая - Google Patents

Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая Download PDF

Info

Publication number
EA015566B1
EA015566B1 EA200701594A EA200701594A EA015566B1 EA 015566 B1 EA015566 B1 EA 015566B1 EA 200701594 A EA200701594 A EA 200701594A EA 200701594 A EA200701594 A EA 200701594A EA 015566 B1 EA015566 B1 EA 015566B1
Authority
EA
Eurasian Patent Office
Prior art keywords
use according
dopamine antagonist
day
pharmaceutical composition
compound
Prior art date
Application number
EA200701594A
Other languages
English (en)
Russian (ru)
Other versions
EA200701594A1 (ru
Inventor
Томас Штёр
Original Assignee
ЮСиБи ФАРМА ГМБХ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05001843A external-priority patent/EP1688137A1/fr
Application filed by ЮСиБи ФАРМА ГМБХ filed Critical ЮСиБи ФАРМА ГМБХ
Publication of EA200701594A1 publication Critical patent/EA200701594A1/ru
Publication of EA015566B1 publication Critical patent/EA015566B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EA200701594A 2005-01-28 2006-01-27 Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая EA015566B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64741005P 2005-01-28 2005-01-28
EP05001843A EP1688137A1 (fr) 2005-01-28 2005-01-28 SPM 927 pour la thérapie adjuvante de la schizophrenie
PCT/EP2006/000722 WO2006079547A2 (fr) 2005-01-28 2006-01-27 Lacosamide pour traitement d'appoint

Publications (2)

Publication Number Publication Date
EA200701594A1 EA200701594A1 (ru) 2008-02-28
EA015566B1 true EA015566B1 (ru) 2011-10-31

Family

ID=36636204

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701594A EA015566B1 (ru) 2005-01-28 2006-01-27 Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая

Country Status (12)

Country Link
EP (1) EP1841417A2 (fr)
JP (1) JP2008528532A (fr)
KR (1) KR20070096058A (fr)
AR (1) AR057643A1 (fr)
AU (1) AU2006208630B2 (fr)
BR (1) BRPI0607043A2 (fr)
CA (1) CA2595330A1 (fr)
EA (1) EA015566B1 (fr)
IL (1) IL183973A0 (fr)
MX (1) MX2007009070A (fr)
NO (1) NO20074361L (fr)
WO (1) WO2006079547A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1873527A1 (fr) 2006-06-30 2008-01-02 Schwarz Pharma Ag Procédé d'identification des modulateurs CRMP
EP1920780A1 (fr) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Composés peptidiques pour le traitement des maladies liées à l'hyperexcitabilité
EA027836B1 (ru) 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP2214657A1 (fr) 2007-10-23 2010-08-11 UCB Pharma GmbH Composés pour le traitement de conditions de démyélinisation
US20100151021A1 (en) * 2008-12-16 2010-06-17 Venkatesh Gopi M Compositions Comprising Melperone
EA029180B1 (ru) 2010-12-02 2018-02-28 Юсб Фарма Гмбх Лекарственная форма лакозамида для приема один раз в сутки
EP2468261A1 (fr) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation de lacosamide
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
CA3047354A1 (fr) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Systeme therapeutique transdermique contenant de l'asenapine et un polysiloxane ou un polyisobutylene
CA3067938A1 (fr) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Systeme therapeutique transdermique contenant de l'asenapine et un polymere hybride acrylique de type silicone
JP7268026B2 (ja) 2017-12-05 2023-05-02 サノビオン ファーマシューティカルズ インク 非ラセミ混合物およびその使用
WO2019113084A1 (fr) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Formes cristallines et leurs procédés de production
CA3101420A1 (fr) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Systeme therapeutique transdermique contenant de l'asenapine
BR112021024380A2 (pt) 2019-06-04 2022-04-19 Sunovion Pharmaceuticals Inc Formulações de liberação modificadas e usos das mesmas
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1243262E (pt) 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CITROME LESLIE: "Schizophrenia and valproate." PSYCHOPHARMACOLOGY BULLETIN. 2003, vol. 37 Suppl 2, 2003, pages 74-88, XP009035196 ISSN: 0048-5764 cited in the application page 76 page 85 *
FOUNTAIN NATHAN V. ET AL.: "Absence of effect of adjunctive SPM 927 on concomitant AED plasma concentrations in subjects with partial seizures." EPILEPSIA, vol. 44, no. Supplement 9, 2003, page 96, XP009028153 & ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY; BOSTON, MA, USA; DECEMBER 05-10, 2003 ISSN: 0013-9580 abstract *
HORSTMANN ROLF ET AL.: "SPM 927 does not interact with valproic acid and carbamazepine." EPILEPSIA, vol. 44, no. Supplement 9, 2003, page 97, XP009028152 & ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY; BOSTON, MA, USA; DECEMBER 05-10, 2003 ISSN: 0013-9580 abstract *

Also Published As

Publication number Publication date
EA200701594A1 (ru) 2008-02-28
WO2006079547A3 (fr) 2006-09-21
NO20074361L (no) 2007-10-26
MX2007009070A (es) 2007-09-12
KR20070096058A (ko) 2007-10-01
AU2006208630B2 (en) 2011-09-29
CA2595330A1 (fr) 2006-08-03
JP2008528532A (ja) 2008-07-31
WO2006079547A2 (fr) 2006-08-03
IL183973A0 (en) 2008-12-29
EP1841417A2 (fr) 2007-10-10
BRPI0607043A2 (pt) 2009-08-04
AU2006208630A1 (en) 2006-08-03
AR057643A1 (es) 2007-12-12

Similar Documents

Publication Publication Date Title
EA015566B1 (ru) Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая
US11529342B2 (en) Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
AU2003227516B2 (en) A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
US20060276412A1 (en) Methods and compositions for managing psychotic disorders
JP2007517901A (ja) 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
MX2008000249A (es) Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
WO2009018368A1 (fr) Traitement d'association à base d'amplificateur du nmda (n-méthyl-d-aspartate), d'inhibiteur de transporteur de glycine, d'inhibiteur de d-amino acide oxydase pour des troubles neuropsychiatriques
CA2530381C (fr) Association d'un antagoniste ou agoniste inverse du recepteur h3 de l'histamine avec un anti-psychotique ou un antidepresseur et son utilisation pour preparer un medicament prevenant des effets indesirables de medicaments psychotropes
EP1758600A1 (fr) Compositions et methodes de traitement des troubles de l'humeur
US20050119249A1 (en) Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
MXPA02004410A (es) Tratamiento de combinacion para la ansiedad y la depresion.
MXPA04005716A (es) Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo.
EP1576985A1 (fr) Utilisation d'antagonistes, d'agonistes partiels ou d'agonistes inverses des recepturs D4 et 5-HT2A
DK2694065T3 (en) COMPOSITION FOR TREATMENT OF DISORDER WITH SEXUAL SEXUAL LISTENING
MXPA02003452A (es) Tratamiento de combinacion de esclerosis multiple (em), otras condiciones de desmielinacion y neuropatia periferica, especialmente neuropatias dolorosas y neuropatia diabetica.
CA2865845A1 (fr) Un metabolite d'iloperidone destine a etre utilise dans le traitement de troubles psychiatriques
CA2461248C (fr) Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a
US20080139573A1 (en) Treatment of resistant Schizophrenia and other CNS disorders
EP1545546B1 (fr) Traitement de la dyskinésie avec des 2,3-benzodiazépines
EP1326616A1 (fr) Nouvelle utilisation de la quetiapine
CN111670041A (zh) 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合
JP2007522175A (ja) 社会恐怖症の治療用の２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル−ベンジル）−２ｓ−フェニル−ピペリジン−３ｓ−イル）アミン
WO2012072665A1 (fr) Compositions comprenant de la pipampérone et des antagonistes/inhibiteurs de la recapture de la sérotonine

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU